SUMMARY Plasma concentrations of a stable prostaglandin F2 a metabolite were measured by radioimmunoassay during and after recovery from acute airway obstruction in 15 infants. Mean (SEM) metabolite concentrations (ng/l) in plasma obtained both before (1033 (418)) and after (1470 (413)) initial treatment for airway obstruction were significantly higher than those obtained from the same subjects after resolution of the obstruction-25-5 (6-6)-and those obtained from two comparison groups.
Acute airway obstruction is commonly diagnosed in children less than 2 years of age. Potential causes include viral bronchiolitis1 and asthma, which is subsequently dia nosed in approximately 30-50% of affected infants. Bronchiolitis and asthma share certain signs including wheezing, hyper-reactivity of the airway, and association with viral infections; a common patho qenesis has been postulated for the two syndromes. Recent investigations support the hypothesis that asthma is an inflammatory disease of the lower airways."6 Increased concentrations of various inflammatory mediators in plasma, including histamine and neutrophil chemotactic factor of anaphylaxis, have been reported during acute asthmatic attacks4 and after bronchial provocation. 5 Welliver et al reported increased concentrations of histamine and respiratory syncytial virus-specific IgE antibodies in nasopharyngeal secretions of children with respiratory syncytial virus bronchiolitis, but did not report on plasma histamine concentrations.7 Measurement of mediators in plasma may be useful as it avoids the dilutional errors common in analysis of nasal washes. Additionally, plasma concentrations might reflect the severity more accurately, as the nasal site is distant from the inflammation in the lower airways.
The purpose of the present study was to determine whether plasma concentrations of a mediator of inflammation with known bronchoconstrictive properties were increased during acute airways obstruction. Specifically, nasal and plasma concentrations of a stable prostaglandin F2 a metabolite were measured in infants during and after recovery from acute airway obstruction.
Patients and methods
This research was approved by the Children's Hospital Human Experimentation Committee. Informed consent was obtained from the parents of all study subjects.
STUDY DESIGN
The criteria for study entry included age less than 1 year, history of rhinorrhea, cough and fever for no more than 48 hours, and airway obstruction defined as wheezing heard on auscultation of the chest associated with tachypnoea. Children with a previous history of wheezing, allergic or immunological disorders, or heart disease were excluded. Infants who fulfilled the entry criteria were enrolled in the study either after evaluation in the emergency department or following admission to hospital. Infants in the first group (n=9) were studied in the outpatient clinical research centre of the Children's Hospital of Pittsburgh. Indwelling venous catheters 1112
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were placed in six of these infants to permit collection of venous blood both before and after treatment had been started with nebulised isoetharine. Blood samples were obtained by needle venipuncture from the remaining six subjects, all of whom were studied within 48 hours of onset of symptoms having received nebulised isoetharine before enrolment. In infants with severe respiratory distress or who did not respond to the bronchodilator, arterial blood obtained for blood gas determination was also assayed for the prostaglandin metabolite. Blood was also obtained from two age matched groups for comparison.
Nasal fluids were collected as previously described,8 cultured for respiratory syncytial virus in HEp2 cells, assayed for respiratory syncytial virus antigen by enzyme linked immunosorbent assay (ELISA) (Ortho Diagnostics),9 and the remainder stored frozen at -70°C until assayed for prostaglandin metabolite. Nasal fluids from a subset of study subjects (n=7) were assayed for protein concentration using a previously described method. 10 The degree of airways obstruction was estimated clinically using the combination of a scoring system and the respiratory rate at the time of each blood collection.
Of the 15 study patients, 13 returned for reevaluation and repeat blood studies about six months after the acute attack of airway obstruction. Each parent was asked whether their child experienced any respiratory symptoms after the resolution of the acute attack. Infants in whom a reference of wheezing and tachypnoea had been documented were assigned to the group with recurrent wheezing, while the others were assigned to the group without recurrent wheezing.
CLINICAL SCORE
Each subject was evaluated by one of two investigators (DS: n=13, or HD: n=2). The results of a preliminary study indicated low interobserver variability in the assessment of physical signs associated with lower airways obstruction. Based on results of the examination, each subject was assigned a numerical score from 0 (least severe) to 3 (most severe) for each of the following variables: cyanosis, rib retraction, air entry, inspiratory:expiratory ratio, level of consciousness, and wheezing. The numerical values for each variable were added to yield a total score, which along with resting respiratory rate, was used to estimate severity.
SUBJECTS
Fifteen infants (mean age 3-4 months, range 1-7) were studied. A positive family history of allergies and asthma was present in nine (62%) and 10 (69%) study subjects, respectively. The duration of symptoms before enrolment into the study was two to six hours in one subject, 12-24 hours in six, and 24-48 hours in the remainder. All subjects presented with tachypnoea, ranging from 52 to 84 breaths/ minute (mean 64.4). Clinical scores on presentation ranged from 2 to 11 (mean 3-4). Of the nine subjects admitted to hospital, two were premature and required mechanical ventilation for respiratory failure. Either respiratory syncytial virus or respiratory syncytial virus antigen was detected in nasal washings of nine of 14 (64%) subjects. At follow up six months after resolution of the acute airway obstruction, seven of 13 subjects (54%) had a history of recurrent wheezing, and one wheezed on auscultation. This infant returned for a second follow up visit at which time no wheezing was detected.
For comparison, two additional groups of age matched children were studied. These comprised infants who either were normal (n=9, no respiratory infection) or had an upper respiratory infection, pneumonia without wheezing, or fever without obvious cause (n=6).
PROSTAGLANDIN METABOLITE ASSAY
Because the half life of prostaglandin F2 a in the circulation is only a few minutes,'1 concentrations of one of its stable metabolites, a 13,14-dihydro-15-keto moeity, were measured using a competitive radioimmunoassay as previously described.4 The rabbit antibody used in this assay (Seragen) displayed the following cross reactivities: prostaglandin F2 1-7%; 13,14-dihydro-15-keto-prostaglandin E2 0*14%; 6-keto prostaglandin F, 0-02%; thromboxane B2 0-02%; prostaglandin E2 0-02%; prostaglandin El 0-02%; 11-beta prostaglandin F2 a (Biomol) 0-02%; and prostaglandin F2 , 0-02% and 15-ketoprostaglandin F2 f3 8-4%. The sensitivity of the assay is 2i7 ng/l and samples with lower concentrations of metabolite are reported as <2*7 ng/l. Plasma prostaglandin metabolite concentrations are expressed as ng/l; concentrations in nasal fluid were analysed as both ng/l and ng/g of protein for normalisation. DATA 
ANALYSIS
Samples obtained from study subjects were grouped by collection time, site of collection (artery, vein, nose), respiratory syncytial virus positivity, and recurrence of wheezing. The mean plasma and nasal prostaglandin metabolite concentrations of the groups were calculated and compared. Indicators Prostaglandin metabolite values before and after initial treatment and after resolution ranged from 74-3600 ng/l, 13-7240 ng/l, and <2-7-84 ng/l, respectively. Concentrations from both before (1033 (418)) and after (1470 (413)) treatment had been started were significantly higher (p<0-005) than those from the same subjects after resolution of symptoms (25.5 (6.6)). The difference between concentrations before and after treatment was not significant and the value after resolution was not significantly different from that of normal infants (42-0 (20.4)), or infants in the comparison group (33-5 (17)). These latter values do not differ from those reported for normal individuals by radioimmunoassay, gas chromatography and mass spectrometry,14 15 More than one blood sample was obtained from six of the subjects during the study period. As shown in fig 2, three representative subjects had increased, decreased, or unchanged plasma prostaglandin metabolite concentrations after bronchodilator treatment had been started. All values returned to normal at the follow up visit, except the one patient who was wheezing at the six month follow up visit. This patient was not wheezing when evaluated one month later, at which time the concentration had returned to normal (6-2 ng/l).
The concentrations (ng/l) in arterial blood obtained after treatment (1782 (432.9), n=5) were higher than those in venous blood taken after treatment from either the same subjects (952-4 (136.2)) or from the whole group (1470 (413-2), n=19), but these differences were not significant. This arterial venous difference was also observed when simultaneous venous (939-2 ng/l) and arterial (2921 ng/l) samples were obtained from one subject who required artificial ventilation for respiratory failure.
Prostaglandin metabolite concentrations in nasal secretions (n=12) ranged from <2-7 to 1645 ng/l, mean 383-8 (120.6) ng/l. After 1781 (1088) . The increases were often accompanied by similar increases in plasma concentrations, but a significant positive correlation between these two variables could not be shown before or after normalisation (Pearson product moment correlation coefficient). 16 Plasma and nasal concentrations of prostaglandin metabolite were compared with corresponding indicators of severity (clinical score and respiratory rate) for each subject. Even though both plasma and nasal metabolite concentrations were often considerably raised in the most severely ill infants, a positive correlation could not be demonstrated for any of the clinical variables using the Spearman rank correlation coefficient. 17 Necessity for hospital admission was also used as an indicator of more severely ill infants, and metabolite concentrations in infants in hospital (1147 (656)) were not significantly different from outpatients (1087 (403)).
Nasal and plasma metabolite concentrations during acute attacks of airways obstruction were compared for infants with and without recurrent wheezing after resolution. Concentrations both before and after treatment were higher in the subjects with recurrent wheezing than in those without, but this difference was significant (p<0-025) only for the The results of this study show for the first time that plasma levels of a prostaglandin F2 a metabolite are considerably increased (fifty fold) in infants with acute airway obstruction, and return to normal after the acute process has resolved. Several pieces of evidence suggest that many of these infants had bronchiolitis, but whether this represented their first episode of asthma is not clear. Lesser increases of the same metabolite were observed during acute asthmatic attacks by our laboratory staff,4 and during provoked episodes of wheezing and bronchospasm by others.14 These increases in plasma concentrations probably reflect much higher local concentrations of the metabolite's active precursor molecule, prostaglandin F2 a, in the tissue of origin. Prostaglandin F2 a is a potent bronchoconstrictor18 and secretogogue,19 the primary synthetic and metabolic site of which is the lung. 3 These observations suggest that prostaglandin F2 a is a mediator of airway inflammation in airway obstructive disorders.
The likely tissue source for the prostaglandin metabolite is the lung, which is a major site for prostaglandin synthesis by the cyclo-oxygenase pathway of arachidonic acid metabolism, and for release and degradation of prostaglandins. Even though the incidence of recurrent wheezin in this study is similar to that reported previously, the follow up period is probably too short to detect all subjects who will ultimately have recurrent wheezing. Indeed, wheezing may not recur until several years after the acute attack of airway obstruction. Further prospective studies of this group are being conducted to clarify this issue. None the less, in the present study, infants who carried on wheezing after resolution of airway obstruction had significantly higher plasma metabolite concentrations during the acute illness than those who did not. This suggests that an increased pulmonary concentration of prostaglandin F2 a predisposes infants to airway hyper-reactivity and recurrences of wheezing or, alternatively, that a relative hyper-responsiveness of prostaglandin synthesising cells is present in the subgroup of infants who later experience recurrences.
The elaboration of prostaglandin F2 a and perhaps other bronchoconstrictive mediators of inflammation during acute airway obstruction should provide a stimulus for the development of specific antiinflammatory agents to supplement bronchodilators in the treatment of infantile airway obstruction. 
